A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors
To determine the safety and efficacy of BLU-285 in patients with advanced GIST and other advanced solid tumors.
Part 1: GIST and other advanced solid tumors
Part 2: GIST with D842 mutation in PDGFRa and GIST with other mutations.
1. Male or female aged 18 or older
2a. Part 1: Patients with advanced solid tumors without available effective therapy. Patients with GIST that cannot be removed surgically and has progressed following treatment with imatinib and at least 1 other therapy. Patients with D842 mutations do not have any prior therapy requirements.
2b. Part 2: Patients with GIST that cannot be removed surgically and has progressed following treatment with imatinib and at least 1 other therapy. Patients with D842 mutations do not have any prior therapy requirements.
3. Patient cannot have a history of a seizure disorder (e.g., epilepsy) or requirement for anti-seizure medication.
Other eligibility criteria apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Patients will receive the study drug until their disease gets worse or they develop intolerable side effects. If their disease was stable, they will be evaluated every 3 months until a new treatment is started or their disease worsens.
Knight Clinical Trials Information Line
Blueprint Medicines Corporation